|
시장보고서
상품코드
2016163
알레르기 치료 시장 보고서 : 유형, 치료법, 제형, 유통 채널, 지역별(2026-2034년)Allergy Treatment Market Report by Type, Treatment, Dosage Form, Distribution Channel, and Region 2026-2034 |
||||||
세계의 알레르기 치료 시장 규모는 2025년에 247억 달러에 달했습니다. 향후 IMARC Group은 2026-2034년에 CAGR 4.72%로 성장하며, 2034년까지 378억 달러에 달할 것으로 예측하고 있습니다.
알레르기 치료는 꽃가루, 곰팡이, 동물의 비듬, 라텍스, 곤충, 식품, 의약품 등의 알레르겐에 대한 비정상적인 반응을 예방하고 치료하는 의료행위입니다. 이들은 면역체계에 의해 히스타민을 분비시켜 염증, 발진, 가려움증, 재채기, 콧물, 눈의 충혈 등을 유발합니다. 또한 꽃가루 알레르기, 천식, 비염, 피부 알레르기, 음식 알레르기, 눈 알레르기 등 다양한 알레르기 증상을 유발할 수 있습니다. 알레르기 치료에는 항알레르기제, 면역요법 등이 있으며, 경구, 흡입기, 비강내 투여 등의 제형으로 투여됩니다. 이러한 치료법은 과민반응과 염증을 줄이고 증상을 완화하며 환자의 삶의 질을 개선하는 데 도움이 됩니다.
알레르기 치료 시장 동향:
전 세계에서 다양한 알레르기의 유병률이 증가하고 있는 것이 시장 성장을 이끄는 주요 요인 중 하나입니다. 이에 따라 정부 및 비정부기구(NGO)의 적극적인 노력으로 알레르기의 폐해와 적절한 치료법에 대한 일반 대중의 인식이 높아지면서 시장 성장을 촉진하고 있습니다. 또한 일반의약품(OTC)에 대한 수요 증가와 더불어 소비자들 사이에서 셀프메디케이션에 대한 관심이 높아진 것도 시장 성장을 촉진하는 또 다른 요인으로 작용하고 있습니다. 또한 알레르기 질환의 진단, 표적화된 개입을 통한 환자 결과 예측, 면역학 데이터 분석, 의료 서비스 개선을 위한 인공지능(AI), 자연 언어 처리(NLP), 머신러닝(ML)의 통합이 시장 성장에 탄력을 받고 있습니다. 이와 더불어, 피하 알레르겐 특이적 면역요법(SCIT)의 효능, 안전성, 면역체계를 변화시켜 전신 증상 완화를 초래하는 능력으로 인해 피하 알레르겐 특이적 면역요법(SCIT)에 대한 수요가 증가하고 있으며, 시장 전망을 밝게 하고 있습니다. 이 밖에도 막대한 의료비 지출, 고령 인구 증가, 새로운 치료법을 위한 광범위한 연구개발(R&D) 활동, 천식 발병률 증가 등의 요인이 시장 성장을 촉진할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 알레르기 치료 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 치료별
제8장 시장 내역 : 제형별
제9장 시장 내역 : 유통 채널별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSA 26.05.06The global allergy treatment market size reached USD 24.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 37.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.72% during 2026-2034.
Allergy treatment is a preventive medical cure for abnormal reactions to allergens, such as pollens, molds, animal dander, latex, insects, food, and medications. They trigger the release of histamine by the immune system that causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes. They can also cause various allergic conditions, including hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic drugs and immunotherapy that can be administered through oral, inhalers, and intranasal dosage forms. These treatment methods help reduce sensitivity and inflammation, decrease symptoms, and improve the quality of the patient's life.
ALLERGY TREATMENT MARKET TRENDS:
The increasing prevalence of various allergies across the globe is one of the primary factors driving the market growth. In line with this, favorable initiatives by governments and non-governmental organizations (NGOs) to sensitize the masses about the adversities of allergies and their appropriate treatment options are favoring the market growth. Furthermore, increasing demand for over-the-counter (OTC) drugs, coupled with a growing inclination toward self-medication among consumers, is acting as another growth-inducing factor. Additionally, the integration of artificial intelligence (AI), natural language processing (NLP), and machine learning (ML) for diagnosing allergic diseases, predicting patient outcomes for targeted interventions, analyzing immunological data, and improving care delivery is providing an impetus to market growth. Apart from this, the increasing demand for subcutaneous allergen-specific immunotherapy (SCIT) due to its effectiveness, safety, and ability to alter the immune system and provide systemic relief is creating a positive outlook for the market. Other factors, including significant healthcare expenditures, increasing geriatric population, extensive research and development (R&D) activities towards novel treatments, and rising incidences of asthma, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Breakup by Type:
- Eye Allergy
- Skin Allergy
- Food Allergy
- Asthma
- Rhinitis
- Others
Breakup by Treatment:
- Anti-Allergy Drugs
- Immunotherapy
Breakup by Dosage Form:
- Oral
- Inhalers
- Intranasal
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Retailers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global allergy treatment market with detailed profiles of all major companies, including:
- AbbVie Inc.
- ALK-Abello A/S
- ALLERGOPHARMA GmbH & Co. KG
- Almirall, S.A
- DBV Technologies
- GSK plc.
- HAL Allergy B.V.
- Nicox
- Novartis Pharmaceuticals Corporation
- Stallergenes Greer
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global allergy treatment market in 2025?
2. What is the expected growth rate of the global allergy treatment market during 2026-2034?
3. What are the key factors driving the global allergy treatment market?
4. What has been the impact of COVID-19 on the global allergy treatment market?
5. What is the breakup of the global allergy treatment market based on the type?
6. What is the breakup of the global allergy treatment market based on the treatment?
7. What are the key regions in the global allergy treatment market?
8. Who are the key players/companies in the global allergy treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Allergy Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Eye Allergy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Skin Allergy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Food Allergy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Asthma
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Rhinitis
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Treatment
- 7.1 Anti-Allergy Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Immunotherapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Dosage Form
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Inhalers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Intranasal
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Retailers
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 ALK-Abello A/S
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 ALLERGOPHARMA GmbH & Co. KG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Almirall, S.A
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 DBV Technologies
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 GSK plc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 HAL Allergy B.V.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Nicox
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Novartis Pharmaceuticals Corporation
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Stallergenes Greer
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.11 Teva Pharmaceutical Industries Ltd.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Viatris Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 AbbVie Inc.
